Overview

Ixekizumab in the Treatment of Bullous Pemphigoid

Status:
Completed

Trial end date:
2019-06-06

Target enrollment:

Participant gender:

Summary

Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

Eli Lilly and Company

Treatments:

Ixekizumab